MedPath

Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer

Phase 2
Completed
Conditions
Rectal Cancer
Interventions
Radiation: External Beam Radiotherapy
Procedure: Surgical Resection
Registration Number
NCT01013805
Lead Sponsor
Trans Tasman Radiation Oncology Group
Brief Summary

The aims of the trial are (1) to determine the tolerability rate in the setting of a multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and complete pathologic response rate in patients with locally advanced rectal cancer who are treated with an integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Previously untreated and pathologically proven adenocarcinoma of the rectum.
  • MRI staged T3 or T4, any N.
  • Lower border of tumour must be within 12 cm of anal verge.
  • Age greater than or equal to 18 years.
  • ECOG Performance Status 0-1 (Appendix 2)
  • Absolute neutrophil count greater than or equal to 1.5 x 109/L, haemoglobin greater than or equal to 90 g/L, and platelets greater than or equal to 100 x 109/L.
  • Adequate renal function: GFR greater than or equal to 55 mL/min (derived from serum creatinine e.g. using the Cockcroft-Gault formula or measured by radioisotopic techniques).
  • Bilirubin and ALT less than or equal to 1.5 x upper limit of normal.
  • No symptomatic peripheral neuropathy greater than or equal to grade 2.
  • Male or non-pregnant, non-lactating female. Patients on study with reproductive potential, or female partners with reproductive potential, must use an effective contraceptive.
  • Has provided written informed consent for participation in this trial
Exclusion Criteria
  • Presence of metastatic disease.
  • Prior pelvic radiotherapy
  • Febrile intercurrent illness or infection.
  • Previous history of unstable angina
  • Cardiac arrhythmia which in the opinion of the investigator would compromise the safe delivery of protocol treatment
  • Acute coronary syndrome even if controlled with medication
  • Myocardial infarction within the last 12 months
  • Concurrent treatment with other anti-cancer therapy.
  • Significant medical condition which in the opinion of the investigator would compromise the planned delivery of the chemotherapy and radiotherapy or which may be potentially exacerbated by these modalities.
  • Locally recurrent rectal cancer.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Arm 1External Beam RadiotherapyIntegrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
Arm 1Surgical ResectionIntegrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
Arm 1OxaliplatinIntegrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
Arm 1FluorouracilIntegrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
Arm 1LeucovorinIntegrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
Primary Outcome Measures
NameTimeMethod
Tolerability Rate of patients treated with integrated pre-operative radiotherapy with FOLFOX chemotherapy regimenEnd of preoperative treatment (11 weeks)
Secondary Outcome Measures
NameTimeMethod
Complete pathologic response rate following the completion of treatmentDetermined post-surgery
Treatment Related Toxicity ratesDetermined after preoperative treatment and 30 days post-surgery
Dose Intensity of the treatment drugEnd of preoperative treatment (11 weeks)

Trial Locations

Locations (1)

Peter MacCallum Cancer Centre

🇦🇺

Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath